retatrutide clinical trial weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Results: 28.3% Weight Loss
Description
1 Tirzepatide, which acts on both the GIP and GLP-1 systems, also substantially cuts appetite and food intake
[DOI] [PubMed] [Google Scholar] Hausdorff WP, Caron MG, Lefkowitz RJ
Variants in FTO rs9939609 and MC4R rs17782313 may correlate with baseline metabolism and appetite regulation, providing additional context beyond standard clinical assessment
Coaching depth: Weekly coaching, dietitian, and mental health support are included in every plan tier, not sold as add-ons
GLP-1 is a promising natural antidiabetic product due to its anorexigenic, insulinotropic, and weight-reducing effects [6]
